Effusion Cytology
Potential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions
Translational Lung Cancer Research 2025 January 24 [Link] Tian Mun Chee, Caeli J Zahra, Kwun M Fong, Ian A Yang, Rayleen V Bowman Abstract Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which may…
Read MoreRole of Immunocytochemistry in the Cytological Diagnosis of Mesothelioma
Acta Cytologica 2024 December 12 [Link] Claire W Michael, Shannon Alexandra Rodgers Abstract Background: Mesothelioma is an aggressive malignancy of the serosal surfaces with very poor prognosis. It traditionally manifests in older patients and at an advanced stage which results in minimal improvement in prognosis despite the recent advances in management. Early detection would therefore…
Read MoreApplication of the international system for reporting serous fluid cytopathology on pleural effusion cytology with paired pleural biopsy: A new insight and novel approach on risk of malignancy
Cytopathology 2024 August 1 [Link] Zahra Maleki, Ashleigh J Graham, Robert Jones, Ricardo Pastorello, Paul Morris, Alessandra C Schmitt, Erika F Rodriguez Abstract Introduction: The risk of malignancy (ROM) remains an area of interest for further evaluation in reporting systems including in International System for reporting serous fluid cytopathology (TIS), which is a standardized system…
Read MoreCharacterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma
Scientific Reports 2024 July 10 [Link] Riki Okita, Tomoya Senoo, Yuka Mimura-Kimura, Yusuke Mimura, Tomoyuki Murakami, Eiji Ikeda, Masanori Okada, Hidetoshi Inokawa, Keisuke Aoe Abstract The clinical impact of soluble molecules in pleural effusion (PE) is unclear in patients with malignant pleural mesothelioma (MPM). In this single-center, retrospective, observational study, we assessed soluble forms of…
Read MoreInvestigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma
Diagnostic Cytopathology 2024 January 20 [Link] Nazli Sena Şeker, Emel Tekin, Güntülü Ak, Muzaffer Metintaş, Selma Metintaş, Emine Dündar Abstract Background: Mesothelioma is a malignant neoplasm with a poor survival rate. We aimed to investigate the importance of BAP1, MTAP (IHC), and p16/CDKN2A homozygous deletion (FISH) in cytologic material obtained from pleural effusion sampling, which…
Read MorePleural Mesothelioma: Advances in Blood and Pleural Biomarkers
Journal of Clinical Medicine 2023 November 9 [Link] Claudio Sorino, Michele Mondoni, Giampietro Marchetti, Sergio Agati, Riccardo Inchingolo, Federico Mei, Sara Flamini, Filippo Lococo, David Feller-Kopman Abstract Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually…
Read MoreContribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology
European Review for Medical and Pharmacological Sciences 2023 October [Link] G Aydogdu, S Özekinci Abstract Objective: The cytological diagnosis of mesothelioma is a controversial issue, and definitive diagnosis often requires ancillary tests. The aim of this study was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss and p16 (CDKN2A) homozygous deletion (HD) on…
Read MoreClaudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study
Diagnostic Cytopathology 2023 October 13 [Link] Vanlal Hruaii, Balamurugan Thirunavukkarasu, Vindhya Prabha, Sandeep Mathur, Venkateswaran K Iyer, Aruna Nambirajan, Deepali Jain Abstract Background: Claudin-4, a tight junction associated protein expressed in epithelial cells, is purported as a highly specific and sensitive marker for epithelial malignancies. Our aim was to assess the sensitivity, specificity and real-time…
Read MoreKrebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Lung Cancer 2023 September 7 [Link] Paul Stockhammer, Hannah Baumeister, Till Ploenes, Francesco Bonella, Dirk Theegarten, Balazs Dome, Christine Pirker, Walter Berger, Luca Hegedüs, Marcell Baranyi, Martin Schuler, Sophie Deshayes, Servet Bölükbas, Clemens Aigner, Christophe Blanquart, Balazs Hegedüs Abstract Objectives: Pleural mesothelioma (PM) is a rare disease with dismal outcome. Systemic treatment options include chemotherapy…
Read MoreMalignant mesothelioma cells with characteristic intracytoplasmic vacuolization and lipids
Diagnostic Cytopathology 2023 August 15 [Link] Satoshi Morito, Hiroshi Yasui, Tomoo Itoh, Shingo Kamoshida, Hiroyuki Ohsaki Abstract In this brief report, we described some uncommon cytomorphological features of malignant mesothelioma (MM) cells in pleural effusions. The tumor cells exhibited abundant cytoplasmic vacuolization, with presence of single or multiple eccentric nuclei in several cells. In the…
Read More